CNS PHARMACEUTICALS, INC.

(CNSP)
  Report
Real-time Estimate Cboe BZX  -  05/19 12:19:26 pm EDT
0.2860 USD   -0.03%
05/16CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
PR
05/13CNS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05/13CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Ending Near Intra-Day Lows

01/06/2022 | 03:56pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BERKELEY LIGHTS, INC. 7.63% 4.93 Delayed Quote.-74.75%
CNS PHARMACEUTICALS, INC. 1.29% 0.289799 Delayed Quote.-59.27%
EARGO, INC. 5.56% 1.425 Delayed Quote.-73.53%
NASDAQ COMP. 0.70% 11496.27 Real-time Quote.-27.02%
STRYKER CORPORATION -0.62% 230.84 Delayed Quote.-13.17%
All news about CNS PHARMACEUTICALS, INC.
05/16CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate..
PR
05/13CNS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/13CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/28CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in ..
PR
04/28CNS Pharmaceuticals Receives Approval for Pivotal Study of Berubicin for Treatment of G..
CI
04/12CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM..
PR
04/06CNS Pharmaceuticals Gets French Approval for Brain Cancer Treatment Study
MT
04/06CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Author..
PR
04/05SECTOR UPDATE : Health Care Stocks Resist Late Tuesday Selloff
MT
04/05SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on CNS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -20,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,61x
Yield 2022 -
Capitalization 11,5 M 11,5 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 4
Free-Float 73,9%
Chart CNS PHARMACEUTICALS, INC.
Duration : Period :
CNS Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CNS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,29 $
Average target price 6,00 $
Spread / Average Target 1 997%
EPS Revisions
Managers and Directors
John M. Climaco Chairman & Chief Executive Officer
Christopher S. Downs Chief Financial Officer
Donald H. Picker Chief Science Officer
Sandra Leta Silberman Chief Medical Officer
Jerzy Gumulka Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CNS PHARMACEUTICALS, INC.-59.27%11
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524